Rinvoq
E697098
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Rinvoq canonical | 1 |
Statements (53)
| Predicate | Object |
|---|---|
| instanceOf |
Janus kinase inhibitor
ⓘ
brand name drug ⓘ pharmaceutical drug ⓘ small molecule drug ⓘ |
| approvalAgency |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | L04AA44 ⓘ |
| commonAdverseEffect |
acne
ⓘ
cough ⓘ elevated cholesterol ⓘ elevated liver enzymes ⓘ fever ⓘ nausea ⓘ upper respiratory tract infection ⓘ |
| contraindication |
known hypersensitivity to upadacitinib
ⓘ
severe hepatic impairment ⓘ |
| countryOfFirstApproval | United States NERFINISHED ⓘ |
| developedBy | AbbVie NERFINISHED ⓘ |
| dosageForm | extended-release tablet ⓘ |
| firstApprovalYear | 2019 ⓘ |
| hasActiveIngredient | upadacitinib ⓘ |
| hasBlackBoxWarning |
major adverse cardiovascular events
ⓘ
malignancy ⓘ serious infections ⓘ thrombosis ⓘ |
| indication |
Crohn's disease
ⓘ
ankylosing spondylitis ⓘ atopic dermatitis ⓘ juvenile psoriatic arthritis ⓘ non-radiographic axial spondyloarthritis ⓘ polyarticular juvenile idiopathic arthritis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
| intendedUse | treatment of inflammatory and autoimmune diseases ⓘ |
| legalStatusInEU | prescription only ⓘ |
| legalStatusInUS | prescription only ⓘ |
| manufacturer | AbbVie NERFINISHED ⓘ |
| mechanismOfAction | selective inhibition of JAK1 ⓘ |
| pharmacologicalClass | JAK inhibitor ⓘ |
| pregnancyCategory | may cause fetal harm (risk-based warning) ⓘ |
| regulatoryStatus | prescription only ⓘ |
| routeOfAdministration | oral ⓘ |
| targets | Janus kinase 1 NERFINISHED ⓘ |
| treats |
active ankylosing spondylitis
ⓘ
active juvenile psoriatic arthritis ⓘ active non-radiographic axial spondyloarthritis ⓘ active polyarticular juvenile idiopathic arthritis ⓘ active psoriatic arthritis ⓘ moderate to severe Crohn's disease ⓘ moderate to severe atopic dermatitis ⓘ moderate to severe rheumatoid arthritis ⓘ moderate to severe ulcerative colitis ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.